ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
-0,01%
Bitcoin
63.040,66
0,24%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. KalVista Pharmaceuticals Inc (KALV)

  7. KalVista Pharmaceuticals Inc (KALV) News

KALV KalVista Pharmaceuticals Inc

12,13
-0,04 (-0,33%)
03 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
KalVista Pharmaceuticals Inc KALV NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-0,04 -0,33% 12,13 22:35:11
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
12,24 11,955 12,48 12,13 12,17
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
02.5.202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
01.5.202412:30BWKalVista Pharmaceuticals Highlights Strategic Plans for..
22.4.202412:30BWKalVista Pharmaceuticals Appoints William C. Fairey to Board..
03.4.202412:30BWKalVista Pharmaceuticals to Present at 23rd Annual Needham..
02.4.202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
18.3.202411:30BWKalVista Pharmaceuticals Presents Real-World Data on Burden..
12.3.202411:30BWKalVista Pharmaceuticals Awarded UK Promising Innovative..
11.3.202421:37EDGAR2Form 8-K - Current report
11.3.202421:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11.3.202411:30BWKalVista Pharmaceuticals Reports Third Fiscal Quarter..
08.3.202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.3.202412:30BWKalVista Pharmaceuticals to Present HAE Attack Journey Data..
07.3.202412:38EDGAR2Form 8-K - Current report
07.3.202412:30BWKalVista Pharmaceuticals Announces Appointment of Benjamin..
06.3.202412:30BWKalVista Pharmaceuticals to Participate in the Leerink..
04.3.202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
27.2.202412:30BWKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE..
26.2.202412:30BWKalVista Pharmaceuticals Presents Additional Phase 3..
22.2.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202419:22EDGAR2Form SC 13D/A - General statement of acquisition of..
22.2.202403:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202403:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202403:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202403:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202403:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.2.202422:49EDGAR2Form SC 13D/A - General statement of acquisition of..
20.2.202412:30BWKalVista Pharmaceuticals Awarded UK Innovation Passport for..
16.2.202422:32EDGAR2Form 8-K - Current report
16.2.202422:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16.2.202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202412:30BWKalVista Pharmaceuticals to Present Phase 3 Sebetralstat..
15.2.202412:30BWKalVista Pharmaceuticals Announces Pricing of a $160.1..
15.2.202402:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202423:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14.2.202422:18BWKalVista Pharmaceuticals Announces Proposed Public Offering..
14.2.202422:14EDGAR2Form 8-K - Current report
13.2.202415:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.2.202415:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.2.202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.2.202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.2.202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.2.202412:55EDGAR2Form 8-K - Current report
13.2.202412:30BWKalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial..
13.2.202402:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09.2.202402:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.2.202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..

Kürzlich von Ihnen besucht

NASDAQ
KALV
KalVista Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten